1月20日,国家药品监督管理局药品审评中心(CDE)官网显示,康哲药业子公司德镁医药的创新药磷酸芦可替尼乳膏拟纳入优先审评。适应症为:用于其他外用药控制不佳或不建议使用时,非免疫功能受损的2岁及以上儿童和成人轻中度特应性皮炎的局部短期和非持续性慢性治疗。芦可替尼乳膏(Opzelura®)是Incyte开发的选择性JAK1/JAK2抑制剂芦可替尼制成的一种创新型乳膏制剂,目前已经美国FDA批准,可...
Source Link1月20日,国家药品监督管理局药品审评中心(CDE)官网显示,康哲药业子公司德镁医药的创新药磷酸芦可替尼乳膏拟纳入优先审评。适应症为:用于其他外用药控制不佳或不建议使用时,非免疫功能受损的2岁及以上儿童和成人轻中度特应性皮炎的局部短期和非持续性慢性治疗。芦可替尼乳膏(Opzelura®)是Incyte开发的选择性JAK1/JAK2抑制剂芦可替尼制成的一种创新型乳膏制剂,目前已经美国FDA批准,可...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.